Esophageal cancer

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 05:15, 26 April 2012 by PeterYang (talk | contribs) (Added regimens)
Jump to navigation Jump to search

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

Please be aware that some regimens listed here are studies for gastric cancer, not esophageal cancer. These regimens were listed as options by the NCCN, Esophageal Cancer version 2.2011, and their inclusion here reflects the overlap between treatments of esophageal and gastric cancer.


Neoadjuvant chemoradiation

Carboplatin (Paraplatin) & Fluorouracil (5-FU)

Regimen

  • Carboplatin (Paraplatin) AUC 6 IV on days 1 & 22
  • Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion on days 1-42
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions given 5 days per week, starting on day 1, for a total dose of 45 Gy. If surgery was contraindicated, total dose was increased to 50.4-56.8 Gy.
  • Upper endoscopy and CT chest and abdomen was performed after completion of chemoradiation
  • Surgery planned to be done 4-6 weeks after finishing chemoradiation

42-day course

References

  1. Zemanova M, Petruzelka L, Pazdro A, Kralova D, Smejkal M, Pazdrova G, Honova H. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. Dis Esophagus. 2010 Feb;23(2):160-7. Epub 2009 Jun 9. link to original article contains protocol PubMed

Carboplatin (Paraplatin) & Paclitaxel (Taxol)

Regimen

  • Carboplatin (Paraplatin) AUC 2 IV on days 1, 8, 15, 22, 29; given second
  • Paclitaxel (Taxol) 50 mg/m2 IV over 1 hour on days 1, 8, 15, 22, 29; given first
  • Concurrent radiation therapy, 1.8 Gy fractions x 23 fractions given 5 days per week, starting on day 1, for a total dose of 41.4 Gy
  • Surgery planned to be done within 6 weeks of finishing chemoradiation

5-week course

Supportive medications:

  • Dexamethasone (Decadron) 10 mg IV 30 minutes prior to paclitaxel
  • Ranitidine (Zantac) 50 mg IV 30 minutes prior to paclitaxel
  • Clemastine 2 mg IV 30 minutes prior to paclitaxel
  • Between paclitaxel & carboplatin: 100 mL NS given over 30 minutes, then ondansetron 8 mg in 100 mL NS given over 30 minutes

References

  1. van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer. 2006 May 22;94(10):1389-94. link to original article contains protocol PubMed

Carboplatin (Paraplatin), Paclitaxel (Taxol), Capecitabine (Xeloda)

Regimen

The primary reference did not specify whether patients were intended to proceed to surgery.

  • Carboplatin (Paraplatin) AUC 1.5 IV on days 2, 9, 16, 23, 30
  • Paclitaxel (Taxol) 45 mg/m2 IV over 1 hour on days 2, 9, 16, 23, 30
  • Capecitabine (Xeloda) 600 mg/m2 PO BID, starting on day 1 and finishing the evening of the last day of radiation therapy
  • Concurrent radiation therapy, 1.8 Gy fractions x 28 fractions given 5 days per week, for a total dose of 50.4 Gy, starting on day 1

6-week course

References

  1. Czito BG, Kelsey CR, Hurwitz HI, Willett CG, Morse MA, Blobe GC, Fernando NH, D'Amico TA, Harpole DH, Honeycutt W, Yu D, Bendell JC. A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1002-7. Epub 2006 Dec 29. link to original article contains protocol PubMed

Cisplatin (Platinol) & Capecitabine (Xeloda)

Regimen

Note: This is listed as a neoadjuvant regimen by the NCCN, Esophageal Cancer version 2.2011, but the study was for patients with stage IV disease. Please reference the original paper, as there were no patients who only received this neoadjuvant treatment, and they did not undergo surgical resection of disease.

  • Cisplatin (Platinol) 30 mg/m2 IV over 1 hour on day 1; given before the first dose of capecitabine
  • Capecitabine (Xeloda) 800 mg/m2 PO BID, 5 days per week while radiation is being given
  • Concurrent radiation therapy, total of 54 Gy given (dose per fraction and total duration of treatment was not specified)

References

  1. Lee SS, Kim SB, Park SI, Kim YH, Ryu JS, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. Jpn J Clin Oncol. 2007 Nov;37(11):829-35. Epub 2007 Oct 19. link to original article contains protocol--please see note above, as patients in this study did not undergo surgery PubMed

Cisplatin (Platinol) & Docetaxel (Taxotere)

Regimen

21-day cycles x 2 cycles, THEN

  • Cisplatin (Platinol) 25 mg/m2 IV on days 1, 8, 15, 22, 29
  • Docetaxel (Taxotere) 20 mg/m2 IV on days 1, 8, 15, 22, 29
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions given 5 days per week, starting on day 1, for a total dose of 45 Gy.
  • Surgery planned to be done 3-8 weeks after finishing chemoradiation

5-week course

References

  1. Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, Balmermajno S, Köberle D, Terraciano L, Schnider A, Bodis S, Popescu R; Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol. 2009 Sep;20(9):1522-8. Epub 2009 May 22. link to original article contains protocol PubMed

Cisplatin (Platinol) & Fluorouracil (5-FU)

Regimen #1, Tepper, et al. 2008

  • Cisplatin (Platinol) 100 mg/m2 IV over 30 minutes on days 1 & 29; given first
  • Fluorouracil (5-FU) 1000 mg/m2/day IV continuous infusion over 96 hours (total dose 4000 mg/m2) on days 1-4, 29-32; given after cisplatin
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions given 5 days per week, then a 5.4 Gy final boost, for a total dose of 50.4 Gy, starting within 24 hours of chemotherapy
  • EGD and CT chest and abdomen done within 4 weeks after finishing radiation therapy. Only patients who still had resectable disease that was stable or responded would proceed to surgery. Surgery was planned to be done 3-8 weeks after finishing chemoradiation.

5.5-week course

Regimen #2, Bedenne, et al. 2007

Study did not show a benefit of surgery after 2 cycles of chemoradiation as compared to additional chemoradiation.

  • Cisplatin (Platinol) 15 mg/m2 IV over 1 hour on days 1-5
  • Fluorouracil (5-FU) 800 mg/m2/day IV continuous infusion over 120 hours (total dose 4000 mg/m2) on days 1-5
  • Conventional radiation therapy, 2 Gy fractions x 23 fractions given 5 days per week, for a total dose of 46 Gy
    • Earlier in the study, some patients instead received split-course radiation therapy, 3 Gy fractions x 5 fractions given on days 1-5. 15 Gy per cycle; total dose after 2 cycles is 30 Gy.
  • Surgery to be done 50-60 days after start of chemoradiation

21-day cycles x 2 cycles

Supportive hydration:

  • 1 liter NS IV over 2 hours before and after cisplatin

References

  1. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007 Apr 1;25(10):1160-8. link to original article contains protocol PubMed
  2. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 1;26(7):1086-92. link to original article contains protocol PubMed

Cisplatin (Platinol) & Fluorouracil (5-FU) -> Paclitaxel (Taxol), Fluorouracil (5-FU), RT

Regimen

28-day cycles x 2 cycles, THEN

  • Paclitaxel (Taxol) 45 mg/m2 IV on days 1, 8, 15, 22, 29
  • Fluorouracil (5-FU) 300 mg/m2/day IV continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions given 5 days per week, for a total dose of 45 Gy

5-week course

References

  1. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006 Aug 20;24(24):3953-8. link to original article contains protocol PubMed

Cisplatin (Platinol) & Irinotecan (Camptosar)

Regimen #1, Ilson, et al. 2011

21-day cycles x 2 cycles, THEN

  • Cisplatin (Platinol) 30 mg/m2 IV over 30 minutes on days 1 & 8; given before irinotecan
  • Irinotecan (Camptosar) 65 mg/m2 IV over 30 minutes on days 1 & 8; given after cisplatin
  • Concurrent radiation therapy, 1.8 Gy fractions x 28 fractions given 5 days per week, for a total of 50.4 Gy given
  • Surgery performed 4-8 weeks after chemoradiation

21-day cycles x 2 cycles

Supportive medications:

  • Dexamethasone (Decadron) 20 mg PO/IV prior to chemotherapy
  • Granisetron 2 mg PO or ondansetron 32 mg IV prior to chemotherapy
  • At least 500 mL D5NS or NS as supportive hydration
  • Atropine 0.5-1 mg IV prn cholinergic symptoms

Regimen #2, Rivera, et al. 2009

21-day cycles x 2 cycles, THEN

  • Cisplatin (Platinol) 30 mg/m2 IV on days 1, 8, 15, 22
  • Irinotecan (Camptosar) 65 mg/m2 IV on days 1, 8, 15, 22
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions given 5 days per week, starting within 24 hours of the first dose of chemotherapy, for a total dose of 45 Gy.
  • Surgery done 5-8 weeks after finishing chemoradiation

5-week course

Regimen #3, Yoon, et al. 2011

Note: In contrast to the original reference, the NCCN, Esophageal Cancer version 2.2011, lists the dosage of preoperative irinotecan as 50 mg/m2.

  • Cisplatin (Platinol) 30 mg/m2 IV on days 1, 8, 22, 29
  • Irinotecan (Camptosar) 65 mg/m2 IV on days 1, 8, 22, 29
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions given 5 days per week, starting within 24 hours of the first dose of chemotherapy, for a total dose of 45 Gy.

5-week course, THEN

  • Surgery done at least 28 days after finishing chemoradiation, then begin adjuvant chemotherapy at least 28 days after surgical resection:
  • Cisplatin (Platinol) 30 mg/m2 IV on days 1 & 8
  • Irinotecan (Camptosar) 65 mg/m2 IV on days 1 & 8

21-day cycles x 3 cycles

Regimen #4, Sharma, et al. 2009

21-day cycles x 2 cycles (2 cycles per NCCN, Esophageal Cancer version 2.2011; abstract did not specify number of cycles)

References

  1. R. Sharma, G. Y. Yang, H. R. Nava, T. L. Demmy, C. E. Nwogu, S. S. Yendamuri, D. Lamonica, W. Tan, R. V. Iyer, N. I. Khushalani. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC). 2009 ASCO Annual Meeting abstract e15619. link to abstract
  2. Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer (Regimen #2, Rivera, et al. 2009, clinicaltrials.gov)
  3. Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massutí B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E; Spanish Cooperative Group for Digestive Tumor Therapy. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1430-6. Epub 2009 Jun 18. link to original article contains protocol PubMed
  4. Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, Kelsen DP, Capanu M, Tang L, Campbell J, Bains M. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 2011 Oct 11. doi: 10.1002/cncr.26591. link to original article contains protocol PubMed
  5. Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 2011 Oct;68(4):863-70. Epub 2011 Feb 1. link to original article contains protocol PubMed

Cisplatin (Platinol) & Paclitaxel (Taxol)

Regimen

  • Cisplatin (Platinol) 75 mg/m2 IV over 2 hours on day 1
  • Paclitaxel (Taxol) 60 mg/m2 IV over 3 hours on days 1, 8, 15, 22
  • Concurrent radiation therapy, 1.5 Gy fractions given twice per day on days 1-5, 8-12, 15-19, with at least 6 hours between fractions, for a total dose of 45 Gy
  • Barium swallow and CT chest and abdomen done about 1 week prior to surgery to rule out metastatic disease
  • Surgery to be done on approximately day 50

4-week course of therapy

Supportive medications:

  • Dexamethasone (Decadron) 20 mg PO given 12 and 6 hours before paclitaxel
  • Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to paclitaxel
  • Cimetidine (Tagamet) 300 mg IV 30 minutes prior to paclitaxel
  • 1 liter D5NS and mannitol 12.5 g bolus IV prior to cisplatin
  • Mannitol 25 g in 1 liter D5NS IV over 4 hours after cisplatin
  • Filgrastim (Neupogen) 5 mcg/kg SC daily, starting 24 hours after the fourth dose of paclitaxel, continuing until absolute neutrophil count >10,000

Regimen #2, Yoon, et al. 2011

  • Cisplatin (Platinol) 30 mg/m2 IV on days 1, 8, 15, 22, 29
  • Paclitaxel (Taxol) 50 mg/m2 IV over 1 hour on days 1, 8, 15, 22, 29
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions given 5 days per week, starting within 24 hours of the first dose of chemotherapy, for a total dose of 45 Gy.

5-week course, THEN

  • Surgery done at least 28 days after finishing chemoradiation, then begin adjuvant chemotherapy at least 28 days after surgical resection:
  • Cisplatin (Platinol) 75 mg/m2 IV on day 1
  • Paclitaxel (Taxol) 175 mg/m2 IV on day 1

21-day cycles x 3 cycles

References

  1. Urba SG, Orringer MB, Ianettonni M, Hayman JA, Satoru H. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer. 2003 Nov 15;98(10):2177-83. link to original article contains protocol PubMed
  2. Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer (Regimen #2, Yoon, et al. 2011, clinicaltrials.gov)
  3. Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 2011 Oct;68(4):863-70. Epub 2011 Feb 1. link to original article contains protocol PubMed

Docetaxel (Taxotere) & Capecitabine (Xeloda)

Regimen

Note: Neither of the references cited for this regimen by the NCCN, Esophageal Cancer version 2.2011, actually contained this regimen. No primary reference could be found for this regimen.

5-week course

Docetaxel (Taxotere) & Fluorouracil (5-FU)

Regimen #1, Hihara, et al. 2007

  • Docetaxel (Taxotere) 7.5 mg/m2 IV over 1 hour on days 1, 8, 22, 29
  • Fluorouracil (5-FU) 250 mg/m2/day IV continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-45
  • Concurrent radiation therapy, 2 Gy fractions x 30-33 fractions given 5 days per week (i.e. on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-45), for a total dose of 60-66 Gy, starting on day 1

Supportive medications:

7-week course

Regimen #2

Note: Neither of the references cited for this regimen by the NCCN, Esophageal Cancer version 2.2011, actually contained this regimen. No primary reference could be found for this regimen.

5-week course

References

  1. Hihara J, Yoshida K, Hamai Y, Emi M, Yamaguchi Y, Wadasaki K. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. Anticancer Res. 2007 Jul-Aug;27(4C):2597-603. link to original article contains protocol PubMed

Oxaliplatin (Eloxatin) & Capecitabine (Xeloda)

Regimen

Primary reference was not able to be obtained to verify this regimen.

5-week course

References

  1. Javle MM, Yang G, Nwogu CE, Wilding GE, O'Malley L, Vinjamaram S, Schiff MD, Nava HR, LeVea C, Clark KR, Prey JD, Smith PF, Pendyala L. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest. 2009 Feb;27(2):193-200. link to original article PubMed

Oxaliplatin (Eloxatin), Docetaxel (Taxotere), Capecitabine (Xeloda)

Regimen

  • Oxaliplatin (Eloxatin) 40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, 29
  • Docetaxel (Taxotere) 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, 29
  • Capecitabine (Xeloda) 1000 mg/m2 PO BID on days 1-7, 15-21, 29-35
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions, for a total dose of 45 Gy. Patients who were no longer surgical candidates received additional radiation therapy to a total dose of 64.8 Gy.
  • Endoscopy, CT scan, and--if available--endoscopic ultrasound for restaging 2-4 weeks after finishing chemoradiation
  • Surgical resection for appropriate candidates during weeks 9-12

5-week course of therapy

Supportive medications:

  • Dexamethasone (Decadron) 4 mg PO every 12 hours before, at the time of, and after docetaxel; first dose the evening before docetaxel
  • "Routine antiemetics"

References

  1. Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA 3rd, Hainsworth JD. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2010 May 1;28(13):2213-9. Epub 2010 Mar 29. link to original article contains protocol PubMed

Oxaliplatin (Eloxatin) & Fluorouracil (5-FU)

Regimen #1, Lorenzen, et al. 2008

  • Oxaliplatin (Eloxatin) 45 mg/m2 IV over 2 hours on days 1, 8, 15, 22, 29
  • Fluorouracil (5-FU) 225 mg/m2/day IV continuous infusion over days 1-33
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions given 5 days per week, for a total dose of 45 Gy
  • Surgery 4-6 weeks after finishing chemoradiation

35-day course

Regimen #2, Khushalani, et al. 2002

Note: In contrast to the original reference, the NCCN, Esophageal Cancer version 2.2011 lists Fluorouracil (5-FU) as being given on days 1-33.

  • Oxaliplatin (Eloxatin) 85 mg/m2 IV over 2 hours on days 1, 15, 29
  • Fluorouracil (5-FU) 180 mg/m2/day IV continuous infusion over days 8-42
  • Concurrent radiation therapy, 1.8 Gy fractions x 20-22 fractions, for an initial total dose of 36-39.6 Gy, started on day 8
    • Followed by off-cord conformal oblique fields, 5.4-9 Gy given to the clinical target volume (CTV). A second off-cord phase to the gross tumor volume (GTV) of 5.4 Gy was then given, for a total dose delivered of 50.4 Gy to the GTV.
  • Upper GI endoscopy and CT chest, abdomen, and pelvis were done after completion of chemoradiation, and patients without progressive stage II-III disease were offered surgery followed by another cycle of oxaliplatin and 5-FU. Patients who could not proceed to surgery were given another 1-2 cycles of oxaliplatin and 5-FU within 2 weeks.

6-week cycle x 1 initial cycle (see above)

References

  1. Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H, Leichman L. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol. 2002 Jun 15;20(12):2844-50. link to original article contains protocol PubMed
  2. Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, Roethling N, Höfler H, Ott K, Peschel C, Siewert JR, Molls M, Lordick F. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer. 2008 Oct 7;99(7):1020-6. Epub 2008 Sep 16. link to original article contains protocol PubMed

Paclitaxel (Taxol) & Capecitabine (Xeloda)

Regimen

Note: Neither of the references cited for this regimen by the NCCN, Esophageal Cancer version 2.2011, actually contained this regimen. No primary reference could be found for this regimen.

5-week course

Perioperative chemotherapy

ECF, "MAGIC Trial"

ECF: Epirubicin, Cisplatin, Fluorouracil

Regimen

21-day cycles x 3 cycles preoperatively, with surgery 3-6 weeks after completing cycle 3. The 3 cycles of postoperative chemotherapy are started 6-12 weeks after surgery.

Supportive medications:

References

  1. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, Ward C, Iveson T, Nicolson M, Hickish T, Hill M, Oates J. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005 Jun 6;92(11):1976-83. link to original article contains protocol PubMed
  2. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. link to original article contains protocol PubMed

ECX

ECX: Epirubicin, Cisplatin, Xeloda

Regimen

This regimen is listed as a perioperative option by the NCCN, Esophageal Cancer version 2.2011, but it is not clearly described as one by the primary reference. Study participants could have had either locally advanced or metastatic disease, and the primary reference did not list a uniform policy about what patients underwent surgery and its timing--although a few patients were mentioned to undergo surgery. No follow-up report for this trial or its additional participants could be found.

21-day cycles x up to 8 cycles; for perioperative use per NCCN, 3 cycles preoperatively and 3 cycles postoperatively would be used

Supportive medications:

  • Dexamethasone (Decadron) 8 mg IV prior to day 1 chemotherapy and 4 mg PO TID x 2 days thereafter
  • "5HT3 antagonist" prior to chemotherapy
  • Metoclopramide (Reglan) 10 mg PO TID x 3 days after day 1 chemotherapy
  • "Standard hydration" for cisplatin
  • Warfarin (Coumadin) 1 mg PO daily as thrombosis prophylaxis, started on day -1

References

  1. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, Ward C, Iveson T, Nicolson M, Hickish T, Hill M, Oates J. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005 Jun 6;92(11):1976-83. link to original article contains protocol PubMed

EOF

EOF: Epirubicin, Oxaliplatin, Fluorouracil

Regimen

This regimen is listed as a perioperative option by the NCCN, Esophageal Cancer version 2.2011, but it is not clearly described as one by the primary reference. Study participants could have had either locally advanced or metastatic disease, and the primary reference did not list a uniform policy about what patients underwent surgery and its timing--although a few patients were mentioned to undergo surgery. No follow-up report for this trial or its additional participants could be found.

21-day cycles x up to 8 cycles; for perioperative use per NCCN, 3 cycles preoperatively and 3 cycles postoperatively would be used

Supportive medications:

  • Dexamethasone (Decadron) 8 mg IV prior to day 1 chemotherapy and 4 mg PO TID x 2 days thereafter
  • "5HT3 antagonist" prior to chemotherapy
  • Metoclopramide (Reglan) 10 mg PO TID x 3 days after day 1 chemotherapy
  • Warfarin (Coumadin) 1 mg PO daily as thrombosis prophylaxis, started on day -1

References

  1. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, Ward C, Iveson T, Nicolson M, Hickish T, Hill M, Oates J. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005 Jun 6;92(11):1976-83. link to original article contains protocol PubMed

EOX

EOX: Epirubicin, Oxaliplatin, Xeloda

Regimen

This regimen is listed as a perioperative option by the NCCN, Esophageal Cancer version 2.2011, but it is not clearly described as one by the primary reference. Study participants could have had either locally advanced or metastatic disease, and the primary reference did not list a uniform policy about what patients underwent surgery and its timing--although a few patients were mentioned to undergo surgery. No follow-up report for this trial or its additional participants could be found.

21-day cycles x up to 8 cycles; for perioperative use per NCCN, 3 cycles preoperatively and 3 cycles postoperatively would be used

Supportive medications:

  • Dexamethasone (Decadron) 8 mg IV prior to day 1 chemotherapy and 4 mg PO TID x 2 days thereafter
  • "5HT3 antagonist" prior to chemotherapy
  • Metoclopramide (Reglan) 10 mg PO TID x 3 days after day 1 chemotherapy
  • Warfarin (Coumadin) 1 mg PO daily as thrombosis prophylaxis, started on day -1

References

  1. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, Ward C, Iveson T, Nicolson M, Hickish T, Hill M, Oates J. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005 Jun 6;92(11):1976-83. link to original article contains protocol PubMed

Definitive chemoradiation (no surgery)

Carboplatin (Paraplatin) & Paclitaxel (Taxol)

See Carboplatin (Paraplatin) & Paclitaxel (Taxol), except patients did not undergo surgery.

Cisplatin (Platinol) & Capecitabine (Xeloda)

Regimen

The study was for patients with stage IV disease.

  • Patients with M1b disease (visceral metastases) received the chemotherapy only part until progression of disease or unacceptable toxicity.
  • Patients with M1a or M1b (non-viscertal metastases) received 2 cycles of the chemotherapy only part, underwent treatment with chemoradiation, and then treatment continued with--presumably, but not outright specified in the paper--chemotherapy only until progression of disease or unacceptable toxicity.

Chemotherapy only part:

21-day cycles

Chemoradiation part:

  • Cisplatin (Platinol) 30 mg/m2 IV over 1 hour on day 1; given before the first dose of capecitabine
  • Capecitabine (Xeloda) 800 mg/m2 PO BID, 5 days per week while radiation is being given
  • Concurrent radiation therapy, total of 54 Gy given. Dose per fraction and total duration of treatment were not specified, but based on other regimens, it is suspected to be either 1.8 Gy x 30 fractions or 2 Gy x 27 fractions.

1-week cycles until radiation therapy is complete

References

  1. Lee SS, Kim SB, Park SI, Kim YH, Ryu JS, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. Jpn J Clin Oncol. 2007 Nov;37(11):829-35. Epub 2007 Oct 19. link to original article contains protocol PubMed

Cisplatin (Platinol) & Docetaxel (Taxotere)

Regimen #1, Li, et al. 2009

  • Cisplatin (Platinol) 80 mg/m2 IV on days 1 & 22
  • Docetaxel (Taxotere) 60 mg/m2 IV on days 1 & 22
  • Concurrent radiation therapy, 1.8-2.0 Gy fractions, 5 days per week, to start within 24 hours of the day 1 of chemotherapy
    • Patients with stage I-III disease received a total dose of 60-64 Gy over 4-6 weeks
    • Patients with stage IV disease (lymph node only) received a total dose of 50-56 Gy

1 cycle of chemoradiation

Supportive medications:

  • Dexamethasone (Decadron) 10 mg PO/IV the day before docetaxel, 30 minutes prior to docetaxel, and the day after docetaxel
  • Diphenhydramine (Benadryl) 40 mg IV prior to chemotherapy
  • Cimetidine (Tagamet) 40 mg IV prior to chemotherapy
  • Granisetron (Kytril) 2 mg IV prior to chemotherapy
  • 1.5-2.0 liters fluids before cisplatin

Regimen #2, Day, et al. 2011

Note: The NCCN, Esophageal Cancer version 2.2011, suggests a wider dose range of 20-30 mg/m2 for both cisplatin and docetaxel. The primary reference also investigated these dose levels, but ultimately recommended 30 mg/m2 dosages for both cisplatin and docetaxel.

  • Cisplatin (Platinol) 30 mg/m2 IV on days 1, 8, 15, 22, 29
  • Docetaxel (Taxotere) 30 mg/m2 IV on days 1, 8, 15, 22, 29
  • Concurrent radiation therapy, 2 Gy fractions x 25 fractions, 5 days per week, for a total dose of 50 Gy, to start within 4 hours after the first dose of chemotherapy.

5-week course

Supportive medications:

  • "Steroid and anti-emetic pre-medication"

References

  1. Li QQ, Liu MZ, Hu YH, Liu H, He ZY, Lin HX. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus. 2010 Apr;23(3):253-9. Epub 2009 Aug 28. link to original article contains protocol PubMed
  2. Day FL, Leong T, Ngan S, Thomas R, Jefford M, Zalcberg JR, Rischin D, McKendick J, Milner AD, Di Iulio J, Matera A, Michael M. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. Br J Cancer. 2011 Jan 18;104(2):265-71. Epub 2010 Dec 14. link to original article contains protocol PubMed

Cisplatin (Platinol) & Fluorouracil (5-FU)

Regimen

  • Cisplatin (Platinol) 75 mg/m2 IV over 30 minutes on day 1
  • Fluorouracil (5-FU) 1000 mg/m2/day IV continuous infusion over 96 hours on days 1-4
  • Concurrent radiation therapy, 1.8 Gy fractions x 28 fractions given 5 days per week, starting on day 1, for a total dose of 50.4 Gy.

28-day cycles x 2 cycles, THEN

28-day cycles x 2 cycles

References

  1. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 1;20(5):1167-74. link to original article contains protocol PubMed

Cisplatin (Platinol) & Irinotecan (Camptosar)

See Cisplatin (Platinol) & Irinotecan (Camptosar) Regimen #1, Ilson, et al. 2011 & Regimen #2, Sharma, et al. 2009.

Cisplatin (Platinol) & Paclitaxel (Taxol)

See Cisplatin (Platinol) & Paclitaxel (Taxol), except patients did not undergo surgery.

Docetaxel (Taxotere) & Capecitabine (Xeloda)

See Docetaxel (Taxotere) & Capecitabine (Xeloda).

Docetaxel (Taxotere) & Fluorouracil (5-FU)

See Docetaxel (Taxotere) & Fluorouracil (5-FU) Regimen #1, Hihara, et al. 2007 & Regimen #2.

FOLFOX 4

FOLFOX: FOLinic acid, Fluorouracil, OXaliplatin

Regimen

Note: In contrast to the original reference, the NCCN, Esophageal Cancer version 2.2011, lists the dosage of leucovorin as 400 mg/m2.

  • Fluorouracil (5-FU) 400 mg/m2 IV bolus, then 600 mg/m2/day IV over 22 hours on days 1 & 2; given after Oxaliplatin (Eloxatin) and Folinic acid (Leucovorin)
  • Folinic acid (Leucovorin) 200 mg/m2 IV over 2 hours on day 1
  • Oxaliplatin (Eloxatin) 85 mg/m2 IV over 2 hours on day 1
  • Concurrent radiation therapy, 2 Gy fractions x 25 fractions given 5 days per week, for a total dose of 50 Gy

14-day cycles x 3 cycles, THEN

14-day cycles x 3 cycles

References

  1. Conroy T, Yataghène Y, Etienne PL, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel X, Lamezec B, Rio E, Le Prisé E, Peiffert D, Adenis A. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer. 2010 Oct 26;103(9):1349-55. Epub 2010 Oct 12. link to original article contains protocol PubMed

Oxaliplatin (Eloxatin) & Capecitabine (Xeloda)

See Oxaliplatin (Eloxatin) & Capecitabine (Xeloda).

Oxaliplatin (Eloxatin), Docetaxel (Taxotere), Capecitabine (Xeloda)

See Oxaliplatin (Eloxatin), Docetaxel (Taxotere), Capecitabine (Xeloda).

Oxaliplatin (Eloxatin) & Fluorouracil (5-FU)

See Oxaliplatin (Eloxatin) & Fluorouracil (5-FU) Regimen #1, Lorenzen, et al. 2008. Note: Regimen #1 was a neoadjuvant regimen, but is also listed under definitive chemoradiation by the NCCN, Esophageal Cancer version 2.2011. See Oxaliplatin (Eloxatin) & Fluorouracil (5-FU) Regimen #2, Khushalani, et al. 2002.

Paclitaxel (Taxol) & Capecitabine (Xeloda)

See Paclitaxel (Taxol) & Capecitabine (Xeloda).

Chemotherapy for metastatic or locally advanced disease (non-radiation/surgery candidate)

Cisplatin (Platinol) & Docetaxel (Taxotere)

Regimen

  • Cisplatin (Platinol) 75 mg/m2 IV over 4 hours on day 1
  • Docetaxel (Taxotere) 75 mg/m2 IV over 1 hour on day 1; the protocol was amended to change the original dose of 85 mg/m2 to 75 mg/m2 based on high incidence of febrile neutropenia

21-day cycles x up to 8 cycles

Supportive medications:

  • 3 liters per day "hyperhydration"
  • Dexamethasone (Decadron) 8 mg PO given 12 hours & 6 hours before docetaxel, then 8 mg PO BID x 4 days after docetaxel
  • 5-HT3 antagonist for emesis prophylaxis
  • Growth factor support allowed, such as with Filgrastim (Neupogen)

References

  1. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. link to original article contains protocol PubMed

CF (FP)

CF: Cisplatin, Fluorouracil
FP: Fluorouracil, Platinol

Regimen #1, Van Cutsem, et al. 2006 & Dank, et al. 2008

28-day cycles, given until progression of disease or unacceptable toxicity

Supportive medications, as described in Dank, et al. 2008:

  • "Hyperhydration" for 2-3 days with each infusion
  • Ondansetron IV for antiemetic prophylaxis
  • Dexamethasone IV for antiemetic prophylaxis, then PO for 2-3 days
  • Metoclopramide for antiemetic prophylaxis
  • Filgrastim (Neupogen) daily SC, starting on day 4, to be continued until ANC > 1 x 10^9/L for grade 3-4 neutropenia, febrile neutropenia, or neutropenic infection
  • Atropine prn cholinergic symptoms
  • Loperamide prn delayed diarrhea

Regimen #2, Lorenzen, et al. 2009

29-day cycles x up to 6 cycles

Regimen #3, Kang, et al. 2009

21-day cycles, given until progression of disease or unacceptable toxicity

Supportive medications:

  • "Hyperhydration" for cisplatin

References

  1. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991-7. link to original article contains protocol PubMed
  2. Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008 Aug;19(8):1450-7. Epub 2008 Jun 16. link to original article contains protocol PubMed
  3. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666-73. Epub 2009 Jan 19. link to original article contains protocol PubMed
  4. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009 Oct;20(10):1667-73. Epub 2009 Jun 23. link to original article contains protocol PubMed

CF & Cetuximab (Erbitux)

CF: Cisplatin, Fluorouracil

Regimen

  • Cisplatin (Platinol) 100 mg/m2 IV over 60 minutes on day 1, given before Fluorouracil (5-FU)
  • Fluorouracil (5-FU) 1000 mg/m2/day IV continuous infusion on days 1-5, given after cisplatin
  • Cetuximab (Erbitux) 400 mg/m2 IV over 120 minutes on cycle 1 day 1, then 250 mg/m2 IV over 60 minutes on days on cycle 1 days 8, 15, 22; then in cycles 2-6, Cetuximab (Erbitux) is 250 mg/m2 IV on days 1, 8, 15, 22

29-day cycles x up to 6 cycles

Supportive medications:

  • "Standard antiemetic prophylaxis and pre- and postcisplatin hydration"

References

  1. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009 Oct;20(10):1667-73. Epub 2009 Jun 23. link to original article contains protocol PubMed

CLF (FLP)

CLF: Cisplatin, Leucovorin, Fluorouracil
FLP: Fluorouracil, Leucovorin, Platinol

Regimen #1, Al-Batran, et al. 2008

Note: In contrast to the original reference, the NCCN, Esophageal Cancer version 2.2011, lists Fluorouracil (5-FU) as being given every 2 weeks rather than the schedule below.

8-week cycles, given until progression of disease or unacceptable toxicity

Supportive medications:

  • Up to 3 liters normal saline as hydration with cisplatin
  • Antiemetic medications per "local protocols"

Regimen #2, Bouche, et al. 2004

14-day cycles x at least 4 cycles or until progression of disease or unacceptable toxicity (primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more regular schedule was used)

Supportive medications:

  • 1 liter hydration over 3 hours before and after cisplatin
  • 5-HT3 antagonist IV before cisplatin
  • Methylprednisolone (Solu-Medrol) 120 mg IV 10 minutes before cisplatin
  • Oral antiemetics and corticosteroids from days 2-5

References

  1. Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive Group. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-28. link to original article contains protocol PubMed
  2. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42. link to original article contains protocol PubMed

CX (XP)

CX: Cisplatin, Xeloda
XP: Xeloda, Platinol

Regimen

21-day cycles, given until progression of disease or unacceptable toxicity

Supportive medications:

  • "Hyperhydration" for cisplatin

References

  1. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666-73. Epub 2009 Jan 19. link to original article contains protocol PubMed

DCF

DCF: Docetaxel, Cisplatin, Fluorouracil

Regimen #1, Van Cutsem, et al. 2006

Note: In contrast to the original reference, the NCCN, Esophageal Cancer version 2.2011, lists each cycle as lasting 28 days.

21-day cycles, given until progression of disease or unacceptable toxicity

Supportive medications:

  • "Appropriate hydration and premedications"

Regimen #2, Roth, et al. 2007

  • Docetaxel (Taxotere) 75 mg/m2 IV over 1 hour on day 1; the protocol was amended to change the original dose of 85 mg/m2 to 75 mg/m2 based on high incidence of febrile neutropenia
  • Cisplatin (Platinol) 75 mg/m2 IV over 4 hours on day 1
  • Fluorouracil (5-FU) 300 mg/m2/day IV continuous infusion on days 1-14

21-day cycles x up to 8 cycles

Supportive medications:

  • 3 liters per day "hyperhydration"
  • Dexamethasone (Decadron) 8 mg PO given 12 hours & 6 hours before docetaxel, then 8 mg PO BID x 4 days after docetaxel
  • 5-HT3 antagonist for emesis prophylaxis
  • Growth factor support allowed, such as with Filgrastim (Neupogen)

References

  1. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991-7. link to original article contains protocol PubMed
  2. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. link to original article contains protocol PubMed

mDCF

mDCF: modified Docetaxel, Cisplatin, Fluorouracil

Regimen #1, Ozal, et al. 2010

21-day cycles

Regimen #2, Shah, et al. 2011

Note: In contrast to the primary reference, the NCCN, Esophageal Cancer version 2.2011 listed this regimen without bevacizumab. Please see below for the original mDCF regimen that included bevacizumab.

42-day cycles, given until progression of disease or unacceptable toxicity

Supportive medications:

  • "Standard premedication and delayed emesis regimens"

References

  1. G. Ozal, M. Dogan, H. Akbulut, B. Yalcin, G. Utkan, Y. Urun, F. Icli. The safety and efficacy of modified-dose docetaxel, cisplatin, and 5-fluorouracil (mDCF) combination in the front-line treatment of advanced gastric cancer. 2010 Gastrointestinal Cancers Symposium abstract 113. link to abstract
  2. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011 Mar 1;29(7):868-74. Epub 2010 Dec 28. link to original article contains protocol PubMed

mDCF & Bevacizumab (Avastin)

mDCF: modified Docetaxel, Cisplatin, Fluorouracil

Regimen

42-day cycles, given until progression of disease or unacceptable toxicity

Supportive medications:

  • "Standard premedication and delayed emesis regimens"

References

  1. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011 Mar 1;29(7):868-74. Epub 2010 Dec 28. link to original article contains protocol PubMed

Docetaxel (Taxotere), Carboplatin (Paraplatin), Fluorouracil (5-FU)

Regimen

21-day cycles

Supportive medications:

References

  1. Y. M. Elkerm, A. Elsaid, S. AL-Batran, C. Pauligk. Final results of a phase II trial of docetaxel-carboplatin-FU in locally advanced gastric carcinoma. 2008 Gastrointestinal Cancers Symposium abstract 38. link to abstract

DOF

DOF: Docetaxel, Oxaliplatin, Fluorouracil

Regimen

14-day cycles

References

  1. V. Shankaran, M. F. Mulcahy, H. S. Hochster, T. Ryan, H. Choi, A. B. Benson. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: Preliminary results of a phase II study. 2009 Gastrointestinal Cancers Symposium abstract 47. link to abstract

ECF

ECF: Epirubicin, Cisplatin, Fluorouracil

Regimen

21-day cycles x up to 8 cycles

Supportive medications (varied depending on reference):

  • 3 liters per day "hyperhydration"
  • 5-HT3 antagonist for emesis prophylaxis
  • Growth factor support allowed, such as with Filgrastim (Neupogen)
  • Ross, et al. 2002 & Cunningham, et al. 2008 used Warfarin (Coumadin) 1 mg PO daily for catheter thrombosis prophylaxis

References

  1. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002 Apr 15;20(8):1996-2004. link to original article contains protocol PubMed
  2. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. link to original article contains protocol PubMed
  3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. link to original article contains protocol PubMed

ECX

ECX: Epirubicin, Cisplatin, Xeloda

Regimen

21-day cycles x up to 8 cycles

Supportive medications:

References

  1. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. link to original article contains protocol PubMed

EOF

EOF: Epirubicin, Oxaliplatin, Fluorouracil

Regimen

21-day cycles x up to 8 cycles

Supportive medications:

References

  1. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. link to original article contains protocol PubMed

EOX

EOX: Epirubicin, Oxaliplatin, Xeloda

Regimen

21-day cycles x up to 8 cycles

Supportive medications:

References

  1. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. link to original article contains protocol PubMed

Fluorouracil (5-FU) & Folinic acid (Leucovorin)

Regimen

14-day cycles x at least 4 cycles or until progression of disease or unacceptable toxicity (primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more regular schedule was used)

References

  1. Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive Group. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-28. link to original article contains protocol PubMed

FLOT

FLOT: Fluorouracil, Leucovorin, Oxaliplatin, Taxotere

Regimen

14-day cycles x up to 8 (or more) cycles

Supportive medications:

References

  1. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jäger E. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008 Nov;19(11):1882-7. Epub 2008 Jul 31. link to original article contains protocol PubMed

FOLFIRI

FOLFIRI: FOLinic acid, Fluorouracil, IRInotecan

Regimen #1, Dank, et al. 2008

  • Fluorouracil (5-FU) 2000 mg/m2/day IV continuous 22-hour infusion on days 1, 8, 15, 22, 29, 36; given after Irinotecan (Camptosar) and Folinic acid (Leucovorin)
  • Folinic acid (Leucovorin) 500 mg/m2 IV over 2 hours on days 1, 8, 15, 22, 29, 36; given second
  • Irinotecan (Camptosar) 80 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, 29, 36; given first

7-week cycles

Supportive medications:

  • Ondansetron for antiemetic prophylaxis
  • Dexamethasone for antiemetic prophylaxis
  • Filgrastim (Neupogen) daily SC, starting on day 4, to be continued until ANC > 1 x 10^9/L for grade 3-4 neutropenia, febrile neutropenia, or neutropenic infection
  • Atropine prn cholinergic symptoms
  • Loperamide prn delayed diarrhea

Regimen #2, Bouché, et al. 2004

14-day cycles x at least 4 cycles or until progression of disease or unacceptable toxicity (primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more regular schedule was used)

Regimen #3, Samalin, et al. 2010 & Samalin, et al. 2011

14-day cycles

References

  1. Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive Group. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-28. link to original article contains protocol PubMed
  2. Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008 Aug;19(8):1450-7. Epub 2008 Jun 16. link to original article contains protocol PubMed
  3. Wolff K, Wein A, Reulbach U, Männlein G, Brückl V, Meier C, Ostermeier N, Schwab SA, Horbach T, Hohenberger W, Hahn EG, Boxberger F. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs. 2009 Mar;20(3):165-73. link to original article PubMed
  4. Samalin E, Afchain P, Thézenas S, Abbas F, Romano O, Guimbaud R, Bécouarn Y, Desseigne F, Edeline J, Mitry E, Bouché O, Adenis A, Aparicio T, Dorval E, Kramar A, Ychou M. Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. Gastroenterol Clin Biol. 2010 Oct 28. [Epub ahead of print] link to original article contains protocol PubMed
  5. Samalin E, Afchain P, Thézenas S, Abbas F, Romano O, Guimbaud R, Bécouarn Y, Desseigne F, Edeline J, Mitry E, Bouché O, Adenis A, Aparicio T, Dorval E, Kramar A, Ychou M. Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):48-54. PubMed

FOLFOX-C (Cetuximab (Erbitux))

FOLFOX-C: FOLinic acid, Fluorouracil, OXaliplatin, Cetuximab

Regimen

Note: This regimen included Cetuximab (Erbitux), but the dosage was not listed in the abstract nor clinicaltrials.gov listing. The NCCN, Esophageal Cancer version 2.2011, listed this regimen without cetuximab.

  • Fluorouracil (5-FU) 500 mg/m2 IV bolus, then 1200 mg/m2/day IV continuous infusion on days 1 & 2; given after Oxaliplatin (Eloxatin) and Folinic acid (Leucovorin)
  • Folinic acid (Leucovorin) 500 mg/m2 IV over 2 hours on day 1, given second
  • Oxaliplatin (Eloxatin) 85 mg/m2 IV over 2 hours on day 1, given first
  • Cetuximab (Erbitux) dosage not described (but based on other applications may be 400 mg/m2 for the first dose, then 250 mg/m2 on subsequent doses) IV over 1-2 hours on days 1 & 8

14-day cycles

References

  1. Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
  2. P. C. Enzinger, B. Burtness, D. Hollis, D. Niedzwiecki, D. Ilson, A. B. Benson, R. J. Mayer, R. M. Goldberg. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. 2010 ASCO Annual Meeting abstract 4006. link to abstract

MCF

MCF: Mitomycin, Cisplatin, Fluorouracil

Regimen

42-day cycles x up to 6 months

Supportive medications:

References

  1. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002 Apr 15;20(8):1996-2004. link to original article contains protocol PubMed

OLF (FLO)

OLF: Oxaliplatin, Leucovorin, Fluorouracil
FLO: Fluorouracil, Leucovorin, Oxaliplatin

Regimen

8-week cycles, given until progression of disease or unacceptable toxicity

Supportive medications:

  • Antiemetic medications per "local protocols"

References

  1. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42. link to original article contains protocol PubMed

Trastuzumab (Herceptin), Cisplatin (Platinol), Capecitabine (Xeloda)

Regimen

21-day cycles, given until progression of disease or unacceptable toxicity

References

  1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Epub 2010 Aug 19. link to original article contains protocol PubMed

Trastuzumab (Herceptin), Cisplatin (Platinol), Fluorouracil (5-FU)

Regimen

21-day cycles, given until progression of disease or unacceptable toxicity

References

  1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Epub 2010 Aug 19. link to original article contains protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Esophageal_cancer&oldid=1299"